Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
(NASDAQ: PGEN) Delayed: 5.36 -0.02 (0.37%)
Previous Close $5.38    52 Week High $ 
Open $5.29    52 Week Low $ 
Day High $5.59    P/E N/A 
Day Low $5.27    EPS $ 
Volume 5,246,930